- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00187343
A Clinical Trial to Reduce Skin Burn Induced by Breast Radiotherapy Using Intensity Modulated Radiation Therapy (IMRT)
A Phase III Study of Adjuvant Radiation Therapy in Early Breast Cancer Comparing the Use of Breast Intensity Modulated Radiation Therapy (IMRT) to Conventional Wedge Technique
Studie Overzicht
Gedetailleerde beschrijving
Description of the Problem:
The majority of breast cancer patients are treated with breast-conserving surgery followed by radiotherapy, giving loco-regional control rates similar to mastectomy. Currently, the "standard" breast radiotherapy technique includes treatment of the entire breast with a tangential opposed pair of photon beams. The standard technique leads to significant acute skin toxicity, ranging from breast erythema to moist desquamation, in approximately 40% of patients. This toxicity may lead to interruptions in treatment delivery; may increase the risk of developing late skin toxicity including telangiectasia, skin fibrosis and chronic breast pain; and may also be associated with a significant decrease in health-related quality of life (HRQOL). Published data from dosimetric studies suggest that dose variations in excess of 10% within the breast may be the most important predictor of acute radiation-induced skin toxicity (RR = 9.7), and that dose toxicity occurs more frequently in the inframamary fold. A study performed at TSRCC shows that intensity modulated radiotherapy (IMRT) allows for significant improvements in dose homogeneity within the breast compared to standard breast radiotherapy techniques. Furthermore, the hot spot over 10% seen in the inframamary fold for patient with large breast volume is removed.
Objectives:
- To determine if the occurence of acute skin toxicity in women receiving adjuvant breast radiation with IMRT is less frequent compared to women treated with conventional technique.
- To determine if the HRQOL scores, and specifically breast module subscale scores, in women receiving adjuvant breast radiation with IMRT is better than HRQOL scores in women receiving conventional technique.
- To perform a comparison of costs in the delivery of breast radiotherapy using IMRT to conventional technique.
- To determine if an increased acute skin toxicity translates into an increased late skin toxicity.
- Hypothesis:
We hypothesize that women receiving adjuvant breast radiation with IMRT will have significantly less acute skin toxicity and improved HRQOL compared to women treated with conventional techniques. We also hypothesize that there would not be increased cost related to IMRT compared to conventional technique.
Research plan: A Phase III randomised controled trial is planned, with blocked stratification on breast size and boost delivery. Eligible women include those who have been referred to TSRCC following breast-conserving surgery. They will be randomized to receive either a conventional technique treatment, either breast IMRT. Acute skin toxicity will be assessed weekly during radiotherapy and up to one month following completion of radiotherapy using the previously validated RTOG acute skin toxicity scale. The occurence, duration and intensity of acute skin toxicity will be compared. HRQOL will be assessed during and after irradiation, using validated EORTC instruments (EORTC QLQ-C30 and QLQ-BR23). 340 patients will be accrued in order to detect a 15% reduction in the ocurence of acute skin toxicity with IMRT using an a=0.05, b=0.80.
Studietype
Inschrijving
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8R6V5
- BC Cancer Agency-Vancouver Island Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M4N3M5
- Sunnybrook and Women's College Health Sciences Centre
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- A confirmed histological diagnosis of breast carcinoma or DCIS;
- Treated by breast conserving surgery;
- Adjuvant radiation to the breast only (less than 3 positive lymph nodes);
- Having a ECOG performance status of 0 or 1.
- Having signed an informed consent.
Exclusion Criteria:
- Patients treated by mastectomy;
- Bilateral breast cancer;
- Having an unhealed surgical scar (skin not closed and/or infection);
- Having had prior radiation to the same breast;
- Having active connective tissue disorder;
- Patient being pregnant.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
---|
Maximum skin toxicity measured weekly during the tratment and bi-weekly up to one month after the end of the treatment and complete resolution of skin reaction using the NCI common toxicity criteria version 3.0 scale
|
Secundaire uitkomstmaten
Uitkomstmaat |
---|
Breast localisation of maximum acute skin toxicity;
|
Time of onset of acute skin toxicity;
|
Pain assessment;
|
Duration of symptoms;
|
Factors associated with acute skin reactions;
|
HRQOL;
|
Drug prescription for skin care.
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Jean-Philippe PIGNOL, MD, PhD, Sunnybrook Health Sciences Centre
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- BreastIMRT
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Borstneoplasmata
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University en andere medewerkersVoltooidDe klinische toepassingsgids van Conebeam Breast CTChina
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
Klinische onderzoeken op Breast IMRT
-
Medical University of GrazVoltooidKwaliteit van het leven | Tevredenheid, patiënt | Complicaties, postoperatief/perioperatiefOostenrijk
-
Institut du Cancer de Montpellier - Val d'AurelleWervingBorstkanker | Kapselcontractuur geassocieerd met borstimplantaatFrankrijk
-
Thurgau Breast CenterWerving
-
Memorial Sloan Kettering Cancer CenterActief, niet wervendBorstkankerVerenigde Staten
-
Royal Marsden NHS Foundation TrustOnbekendBorstkankerVerenigd Koninkrijk
-
Abramson Cancer Center of the University of PennsylvaniaVoltooidSymptomatische borstknobbelVerenigde Staten
-
TaiHao Medical Inc.Actief, niet wervendBorstkanker | Borst ziektenTaiwan
-
Cancer Institute and Hospital, Chinese Academy...OnbekendKleincellige longkankerChina
-
University of Sao PauloOnbekendKwaadaardig neoplasma van de borstBrazilië
-
CairnSurgical, Inc.GeschorstBorstkanker VrouwVerenigde Staten, Canada, Verenigd Koninkrijk